ストックスクリーナーアプリを入手
0.346
3.62%
-0.013
前日終値:
$0.359
開ける：
$0.3606
24時間の取引高:
375.89K
Relative Volume:
0.37
時価総額：
$18.44M
収益：
-
当期純損益:
$-24.08M
株価収益率:
-0.4036
EPS:
-0.8572
ネットキャッシュフロー:
$-14.75M
1週間 パフォーマンス:
+3.28%
1か月 パフォーマンス:
-22.80%
6か月 パフォーマンス:
-62.92%
1年 パフォーマンス:
-80.78%
1日の値動き範囲:
$0.342
$0.3757
1週間の範囲:
$0.305
$0.38
52週間の値動き範囲:
$0.26
$1.85
Iterum Therapeutics Plc Stock (ITRM) Company Profile
ITRM を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ITRM
Iterum Therapeutics Plc
|
0.346 | 19.13M | 0 | -24.08M | -14.75M | -0.8572 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.75 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
807.70 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
395.33 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
796.67 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
169.28 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
Iterum Therapeutics Plc Stock (ITRM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2021-05-28 | アップグレード | Gabelli & Co | Sell → Hold |
| 2021-03-15 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2020-06-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-01-21 | ダウングレード | Gabelli & Co | Buy → Sell |
| 2019-12-11 | ダウングレード | SVB Leerink | Outperform → Mkt Perform |
| 2019-06-21 | 開始されました | H.C. Wainwright | Buy |
すべてを表示
Iterum Therapeutics Plc (ITRM) 最新ニュース
Why Iterum Therapeutics plc stock remains a top recommendationStock Buyback Updates & Market Monitoring and Alerts - ulpravda.ru
Will Iterum Therapeutics plc stock benefit from green energy trends2026 world cup usa national team qualification star players possession football odds analysis analysis - ulpravda.ru
Iterum Therapeutics expands market access for ORLYNVAH antibiotic - Investing.com
Iterum Therapeutics provides business update - marketscreener.com
Iterum Therapeutics Provides Business Update - The Manila Times
New antibiotic ORLYNVAH could reach 34M+ people pending FDA feedback - Stock Titan
Analyzing Iterum Therapeutics (NASDAQ:ITRM) & Savara (NASDAQ:SVRA) - Defense World
Why hedge funds are buying Iterum Therapeutics plc stockWeekly Trade Analysis & Capital Efficient Trade Techniques - Улправда
Iterum Therapeutics secures major PBM agreement for antibiotic By Investing.com - Investing.com Nigeria
Iterum Therapeutics (ITRM) Secures Key PBM Agreement and Expands Patent Portfolio - GuruFocus
Iterum Therapeutics secures major PBM agreement for antibiotic - Investing.com
New PBM deal could open ORLYNVAH access to 40M more people in 2026 - Stock Titan
Iterum Therapeutics faces Nasdaq listing compliance challenge - MSN
Iterum Therapeutics Faces Nasdaq Listing Compliance Challenge - The Globe and Mail
Iterum Therapeutics receives Nasdaq notice on listing compliance By Investing.com - Investing.com Australia
Iterum Therapeutics plc Stock Analysis and ForecastEarnings Forecast Updates & Fast Profit Stock Ideas - earlytimes.in
Iterum Therapeutics receives Nasdaq notice on listing compliance - Investing.com
Iterum Therapeutics (NASDAQ: ITRM) discloses Nasdaq delisting risk on value, price - Stock Titan
Iterum Therapeutics Plc (ITRM) can make a big difference with a little luck - setenews.com
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH By Investing.com - Investing.com Nigeria
Iterum Therapeutics expands reimbursement coverage for ORLYNVAH - Investing.com
ITRM Expands ORLYNVAH Access and Secures Key Medicare Part D Agr - GuruFocus
Iterum Therapeutics (Nasdaq: ITRM) inks Medicare Part D deal, EU patent to 2039 - Stock Titan
Iterum Therapeutics (ITRM) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Taking on analysts’ expectations and winning: Iterum Therapeutics Plc (ITRM) - setenews.com
Iterum Therapeutics Plc (ITRM) Performance and Fundamentals Dashboard tells a completely different story - Setenews
Iterum’s antibiotic ORLYNVAH now available through McKesson By Investing.com - Investing.com Nigeria
Iterum’s antibiotic ORLYNVAH now available through McKesson - Investing.com
Iterum Therapeutics (ITRM) Expands Product Availability and FDA Clearance - GuruFocus
Iterum (NASDAQ: ITRM) Adds McKesson for ORLYNVAH as Sulopenem Disc Gains FDA 510(k) - Stock Titan
Q3 2025 Iterum Therapeutics PLC Earnings Call Transcript - GuruFocus
Is Iterum Therapeutics plc stock attractive after correctionPortfolio Update Report & Growth Oriented Trading Recommendations - newser.com
Why retail investors favor Iterum Therapeutics plc stockJuly 2025 Sentiment & Accurate Technical Buy Alerts - newser.com
Can Iterum Therapeutics plc stock maintain operating marginsJuly 2025 Weekly Recap & Trade Opportunity Analysis - newser.com
Iterum Therapeutics director Dunne buys $2,191 in shares By Investing.com - Investing.com Nigeria
Dir Dunne Buys 6,000 ($2.2K) Of Iterum Therapeutics PLC [ITRM] - TradingView
[Form 4] Iterum Therapeutics plc Insider Trading Activity - Stock Titan
Can Iterum Therapeutics plc stock resist market sell offs2025 Big Picture & Fast Gain Swing Alerts - newser.com
Iterum Therapeutics Plc (ITRM) 財務データ
収益
当期純利益
現金流量
EPS
5.77%
大文字化:
|
ボリューム (24 時間):